Free Trial

Profit from the Green Wave: Top Cannabis Stocks to Watch

Marijuana flower buds. — Photo

Key Points

  • The cannabis sector is undergoing a positive transformation driven by a shifting regulatory landscape, with increasing acceptance of medical and recreational cannabis.
  • Strong market fundamentals are driving growth within the cannabis industry.
  • While the cannabis sector presents risks, investors can navigate those risks by conducting thorough research and maintaining a long-term perspective.
  • MarketBeat previews top five stocks to own in November.

The cannabis sector has captivated investors, promising a green rush of potential profits. However, the path to profitability has been rocky, marked by regulatory hurdles, intense competition, and, at times, a volatile market. Many investors are left wondering: Is the cannabis sector still a viable long-term investment, or is the green rush fading? While not simple, the answer increasingly indicates a positive outlook driven by evolving regulations and strong market fundamentals.

A Budding Legal Landscape

The cannabis industry is undergoing a significant transformation that is being driven by a changing regulatory environment. The acceptance of medical and recreational cannabis is increasing across many jurisdictions. This trend is particularly evident in the United States, where a growing number of states have legalized recreational cannabis, creating an expanding market.

While federal legalization in the U.S. remains a hurdle, the potential for it is undeniable. Should it occur, federal legalization would likely trigger a significant surge in industry growth and investment, leading to market stability and a more favorable business environment. This evolving regulatory landscape represents a key driver for the cannabis sector, making it an increasingly attractive investment opportunity for those with a long-term perspective.

Fueling the Green Rush: Market Drivers

The cannabis sector's growth is driven by multiple factors that make it increasingly attractive for investors. Consumer demand is surging, fueled by shifting perceptions of cannabis and the increasing availability of diverse products catering to a wide range of consumer preferences.

Moreover, the medical cannabis segment is experiencing rapid growth, driven by advancements in research and the development of new cannabis-based therapies. Medical cannabis is being explored for its potential to treat a wide range of conditions, creating new opportunities for companies focused on this sector.

Finally, the cannabis market is expanding beyond established jurisdictions like Canada and the United States. As more countries legalize cannabis, the global market is poised to reach new heights, offering significant growth opportunities for cannabis companies with international reach.

Leading Cannabis Companies Show Signs of Progress 

The surge in consumer demand, fueled by changing perceptions and diverse product offerings, attracts significant investment in the cannabis sector. This is evident in the performance of leading companies, many demonstrating a shift towards profitability and a more focused approach to growth.

Aurora Cannabis Today

Aurora Cannabis Inc. stock logo
ACBACB 90-day performance
Aurora Cannabis
$5.32
-0.08 (-1.48%)
(As of 01:50 PM ET)
52-Week Range
$2.84
$9.35

For example, Aurora Cannabis NASDAQ: ACB recently achieved a significant milestone by reporting positive free cash flow for the first time. Aurora’s earnings report for the first quarter of fiscal 2025 revealed a positive free cash flow of $6.5 million, reflecting a strategic focus on cost management and operational efficiency.

This shift is further exemplified by Aurora's strategic move towards the higher-margin medical cannabis segment, leveraging its expertise and resources to capitalize on the growing demand for medical cannabis products. In Q1 2025, Aurora reported record revenue in its global medical cannabis segment, indicating a successful shift towards this lucrative niche.

While Aurora has made significant progress, it still faces challenges, such as ongoing competition and the need for continued fiscal discipline. However, the company's recent achievements signal a positive trajectory for its future, especially considering its debt-free status, which allows for more financial flexibility.

Canopy Growth NASDAQ: CGC has taken a different path, prioritizing profitability and cost control over rapid growth. This strategic shift has significantly improved the company's Adjusted EBITDA, demonstrating its commitment to generating sustainable profits. In Q1 2025, Canopy's Adjusted EBITDA loss narrowed by over 75% compared to the previous year, highlighting the company's success in cost control and operational efficiency. 

Canopy Growth Today

Canopy Growth Co. stock logo
CGCCGC 90-day performance
Canopy Growth
$4.36
-0.05 (-1.13%)
(As of 01:50 PM ET)
52-Week Range
$2.76
$14.92
Price Target
$3.50

This success is also reflected in the company's recent debt reduction efforts, securing a favorable amendment to its term loan agreement, further enhancing its financial flexibility. The company's focus on expanding into key markets like Germany, where it is augmenting its Canadian-sourced flower with EU-based supply to meet growing demand, showcases its ambition to capture a larger share of the global medical cannabis market.

Canopy Growth, like Aurora, still needs to address its ongoing losses. Despite recent improvements, the company remains unprofitable, which is a concern for investors seeking a consistent return on their investment. Additionally, the cannabis industry is prone to volatility, and Canopy's stock price has been highly volatile in recent years, requiring investors to have a strong risk tolerance.

Beyond the Individual Stock: The Power of Cannabis ETFs

AdvisorShares Pure US Cannabis ETF Today

AdvisorShares Pure US Cannabis ETF stock logo
MSOSMSOS 90-day performance
AdvisorShares Pure US Cannabis ETF
$7.03
+0.06 (+0.86%)
(As of 02:08 PM ET)
52-Week Range
$4.92
$11.36
Dividend Yield
0.00%
Assets Under Management
$872.42 million

For investors seeking diversified exposure to the cannabis sector without choosing individual stocks, Cannabis ETFs offer a convenient option. The AdvisorShares Pure U.S. Cannabis ETF NYSEARCA: MSOS is a good starting point, offering investors a basket of publicly traded U.S. cannabis companies.

While ETFs can provide diversification and access to a broader market, it's important to remember that they are not without risks. ETFs are subject to market volatility, and the performance of the underlying companies within the ETF can impact their performance.

The Green Rush Continues

While the path has not been easy, the cannabis sector continues to demonstrate significant potential for long-term growth. The changing regulatory environment is creating a more favorable landscape for cannabis companies, while solid market fundamentals are driving consumer demand and fueling industry expansion. 

The ongoing developments in medical cannabis research are further bolstering the sector's potential, while the emergence of new markets and the growing popularity of diverse cannabis products are contributing to the industry's growth trajectory.

Investors who conduct thorough research, manage risk effectively, and maintain a long-term perspective can position themselves to capitalize on the potential rewards of this evolving and dynamic sector. The green rush may be ongoing, but navigating its complexities requires careful planning and a thoughtful investment strategy.

Where should you invest $1,000 right now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Jeffrey Neal Johnson
About The Author

Jeffrey Neal Johnson

Contributing Author

Retail and Technology Stocks

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Aurora Cannabis (ACB)
1.007 of 5 stars
$5.31-1.7%N/A-3.79BuyN/A
Canopy Growth (CGC)
1.1513 of 5 stars
$4.34-1.6%N/A-0.68Reduce$3.50
AdvisorShares Pure US Cannabis ETF (MSOS)N/A$7.04+1.0%N/A12.20N/AN/A
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

ETF Battle: SPY or VOO – Which One Should You Buy?

ETF Battle: SPY or VOO – Which One Should You Buy?

Comparing S&P 500 ETFs: SPY and VOO. Thomas and Chris break down the key differences and similarities between these two giants in the ETF world.

Related Videos

Set It and Forget It: Top ETFs for Stress-Free Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines